Hot or Not, Stock Market Edition: 10/10/2025

Happy Friday! Here’s what’s sizzling and what’s fizzling today: 

• Hot: Why Intuitive Surgical (ISRG) has buy the dip potential; a big win for Gilead Sciences (GILD)
• Not: Unilever (UL) isn’t faring so well after its Ben & Jerry’s breakup; Procter & Gamble (PG) dips after cutting international operations 

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT: Can you say buy the dip? Intuitive Surgical (ISRG) is down roughly 15% in the past 3 months, but things could be turning around. Here’s why: 1) The company just scored FDA clearance to expand AI and advanced imaging in its Ion Endoluminal System 2) It’s a trending market niche — as we reported in this article, the future looks bright for robotics stocks, including ISRG — click here to find out why. In terms of the Zen Ratings, ISRG earns a B, with standout Component Grades for Financials, Sentiment, and our proprietary AI factor (find out how it works here). Share price movement may have taken a breather, but analysts and recent insider activity are calling for a positive turn, and the company’s leadership in the surgical robotics niche keeps it firmly in growth territory.

🥶 NOT: Unilever (UL) is down about 8% in the past month — timing that lines up with its onscious uncoupling with Ben & Jerry’s. The stock also just got downgraded in our Zen Ratings system to a C (Hold). Digging into the Component Grades to see why, you’ll see a D for Growth and lackluster Cs for Value, Momentum, and Safety. Until Unilever can cook up more consistent top-line expansion and get Wall Street back on its side, it may struggle to ignite any true bullish momentum. 

🔥 HOT: Back off, copycats! Gilead Sciences (GILD) recently settled its high-profile patent litigation for Biktarvy, its blockbuster HIV treatment, pushing back the advent of generic copycats until 2036. The knock-on effect? Turbocharged investor confidence that sent the stock climbing (6% in the past week). GILD enjoys a Zen Rating of B (Buy), ranking in the 91st percentile of the thousands of stocks we track. It’s further boosted by high Component Grades for Value, Safety, and Financials (all B's), suggesting stability and smart management. On top of that, GILD is in a trending market niche — the General Drug Manufacturing industry currently earns an Industry Grade of A. The bottom line? With generics warded off, Gilead could reward bold buyers for the long haul. 

🥶 NOT: Procter & Gamble (PG) is down about 5% in the past month. The downtrend seems to have started on news about cutting international operations, signaling trouble with international sales and a slowdown. But it may be part of a bigger trend — the Household & Personal Product industry earns a D rating from our quant ratings system. (Here’s why industry ranking matters.) PG itself earns a C (Hold) rating, hampered by uninspiring Value, Growth, and Momentum grades (all C’s) and a D for Sentiment. Safety is the lone bright spot—the stock is rock solid financially (A in Safety, B in Financials)—but as investors know, safety alone doesn’t move the needle when growth stalls out. 

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.